Lungcancer Clinical Trial
— RexochirOfficial title:
Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer
This randomized controlled trial will evaluate the effect of a preoperative rehabilitation program at home in patients resected for lung cancer, comparing a control group (C group) receiving only chest physiotherapy and a rehabilitation group (R group) receiving both a training program at home and chest physiotherapy
Status | Recruiting |
Enrollment | 90 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients diagnosed for lung cancer (or highly suspicious for cancer tumor) eligible for resection surgery (lobectomy or pneumonectomy) - Age > 18 years - Presence of Chronic Obstructive Pulmonary Disease (COPD) stages 2-4 of Gold (forced expiratory volume (FEV )/ forced vital capacity (FVC) <70%, FEV <80% of predicted) and Exertional dyspnea stage MMRC (Medical Research Council) > 1 - Patients must provide written consent - Member of social security scheme Exclusion Criteria: - Patients refusing to participate - COPD stage 1 Gold (VEMS >= 80% of the theoretical value) - Presenting an operating contraindication during the initial maximal exercise test - Presenting cardiac or vascular contraindication to achieve the readaptation program - Patient living alone at home - Patient with ventilatory assistance at home (oxygen therapy or noninvasive ventilation (NIV)) - With exercise hypoventilation (PaCO2 >45 mmHg) - Cognitive difficulty - unable major - pregnancy, - patients deprived of liberty by a court or administrative decision |
Country | Name | City | State |
---|---|---|---|
France | Centre de Recherche en Nutrition Humaine | Clermont-Ferrand | |
France | Centre Jean Perrin | Clermont-Ferrand | |
France | CHU Clermont Ferrand, Gabriel Montpied, service de médecine du sport et explorations fonctionnelles, | Clermont-Ferrand | |
France | CHU Grenoble, Hôpital Michallon | Grenoble | |
France | Hospices Civiles de Lyon, groupement hospitalier Est, Hopital Louis Pradel | Lyon | |
France | CHU Saint-Etienne, CHU Hopital Nord | Saint Etienne |
Lead Sponsor | Collaborator |
---|---|
Centre Jean Perrin |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hospital length of stay after resection for lung cancer | the date of discharge will be the real day of discharge from surgery department or the day where the patient will be medically considered as outgoing | time from the date of the surgery (Day 0) until the date of discharge (Day n) (assessed up to 56 days) | |
Secondary | the number of complications | during the stay in the surgery department or the intensive care unit (up to 56 days) | ||
Secondary | peak oxygen consumption | evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).
evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5) |
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5) | |
Secondary | 6 minutes walking distance | evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).
evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5) |
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5) | |
Secondary | maximal voluntary quadriceps strength | evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).
evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5) |
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5) | |
Secondary | maximal inspiratory and expiratory strength | evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).
evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5) |
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5) | |
Secondary | real length of stay | the real day of discharge from surgery department | between the first postoperative day (Day 1) and the real discharge date (up to 56 days) | |
Secondary | body composition (bioimpedancemetry) | evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).
evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5) |
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5) | |
Secondary | oxidative adaptations of the muscle | optional ancillary study on quadricipal and intercostal muscle biopsies. | evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2 after intervention : at the date of surgery (during the surgical time at Day 0 week 6) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|
||
Completed |
NCT02285426 -
HD+ I-scan Bronchoscopy Vascular Abnormalities Detection Multicenter Study
|
||
Completed |
NCT04321499 -
SHOX2_PTGER4 DNA Methlyation in Lung Cancer
|
||
Completed |
NCT02962999 -
Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation
|
Phase 4 | |
Completed |
NCT02185690 -
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
|
Phase 1 | |
Recruiting |
NCT02977663 -
Imaging Multiparametric/Multimodality for Lungcancer
|
N/A |